

Examiner Signature	/Marianne Allen/	Date Considered	11/27/2007
-----------------------	------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA, 22313-1450.

Computer-generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	To Be Assigned	
			Filing Date	January 23, 2006	
			First Named Inventor	Monaci, et al.	
			Group Art Unit		
Examiner Name					
Sheet	2	of	3	Attorney Docket Number	ITR0065YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Bargmann, et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein", Nature, Vol. 319, 16 January 1986, pp. 226-230.
		Ben-Levy, et al., "A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway", EMBO Journal, Vol. 13, No. 14, pp. 3302-3311, 1994.
		Coussens, et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene", Science, Vol. 230, pp. 1132-1139, December 6, 1985.
		Disbrow, et al., "Codon optimization of the HPV-16 E5 gene enhances protein expression", Virology, Vol. 311, pp. 105-114, 2003.
		Disis, et al., "Cancer Vaccines Targeting the Her2/neu Oncogenic Protein", Seminars in Oncology, Vol. 28, No. 6, Suppl. 18, December 2001, pp. 12-20.
		Disis, et al., "Generation of T-Cell Immunity to the Her-2/neu Protein After Active Immunization With Her-2/neu Peptide-Based Vaccines", Journal of Clinical Oncology, Vol. 20, No. 11, June 1, 2002, pp. 2624-2632.
		Disis, et al., "Her-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer", Advances in Cancer Research, Vol. 71, pp. 343-371, 1997.
		Disis, et al., "Oncogene proteins as tumor antigens", Current Opinion in Immunology, Vol. 8, 1996, pp. 637-642.
		Fisk, et al., "Identification of Naturally Processed Human Ovarian Peptides Recognized by Tumor-Associated CD8+ Cytotoxic T Lymphocytes", Cancer Research, Vol. 57, pp. 87-93, January 1, 1997.
		Foy, et al., "Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor", Vaccine, Vol. 19, pp. 2598-2606, 2001.
		Gallo, et al., "Xenogeneic Immunization in Mice Using HER2 DNA Delivered by an Adenoviral Vector", Int. J. Cancer, Vol. 113, pp. 67-77, 2004.
		Ikemura, "Codon Usage and tRNA Content in Unicellular and Multicellular Organisms", Mol Biol. Evol. Vol. 2, No. 1, pp. 13-34, 1985.
		Ioannides, et al., "Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the Her-2/neu Proto-oncogene", Cellular Immunology, Vol. 151, pp. 225-235, 1993.
		King, et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma", Science, Vol. 229, No. 4717, pp. 974-976, 1985.
		Klapper, et al., "Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors", Adv. Cancer Res., Vol. 77, pp. 25-79, 2000.

Examiner Signature	/Marianne Allen/	Date Considered	11/27/2007
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer processed form: IDS (IDS Folder), Merck & Co., Inc., -7/12/2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: AM

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	To Be Assigned 10/565418	
			Filing Date	January 23, 2006	
			First Named Inventor	Monaci, et al.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	ITR0065YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Leder, et al., "Enhancement of Capsid Gene Expression: Preparing the Human Papillomavirus Type 16 Major Structural Gene L1 for DNA Vaccination Purposes", J. of Virol., Vol. 75, No. 19, pp. 9201-9209, Oct. 2001.
		Lustgarten, et al., "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A2.1 and Human CD.8", Human Immunology, Vol. 52, pp. 109-118, 1997.
		Messerle, et al., "NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant", Mol. and Cell. Endo., Vol. 105, pp. 1-10, 1994.
		Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 13, No. 9, pp. 777-783, 1993.
		Nakamura, et al., "Codon usage tabulated from the international DNA sequence databases: Its status 1999", Nucleic Acids Research, Vol. 27, No. 1, pp. 292, 1999.
		Peoples, et al., "T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role", PNAS, USA, Vol. 92, pp. 6547-6551, 1995.
		Press, et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues", Oncogene, Vol. 5, pp. 953-962, 1990.
		Shih, et al., "Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts", Nature, Vol. 290, pp. 261-264, March 19, 1981.
		Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer", Science, Vol. 244, 707-712, May 12, 1989.
		Slichenmyer, et al., "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases", Seminars in Oncology, Vol. 28, No. 5, Suppl. 16, October 2001, pp. 67-79.
		Yamamoto, et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", Nature, Vol. 319, pp. 230-234, January 22, 1986.
		Yarden, et al., "Biology of HER2 and Its Importance in Breast Cancer", Oncology, Vol. 61 (Suppl. 2), pp. 1-13, 2001.
		Yoshino, et al., "HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer", Cancer Research, Vol. 54, pp. 3387-3390, 1994.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

Examiner Signature	/Marianne Allen/	Date Considered	11/27/2007
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005